EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mutation‐Immune Crosstalk Contextualizes CAF‐Associated ARPC1A Programs and Cisplatin Response in Gastric Cancer

Deyi Lu, Fanlai Meng, Weiying Zhou, Yifei Hu, Gaosha Li, Jiahao Ge iD, Qing Zhang iD, Qi Min iD

Human Mutation · 2026-01 · 2026 (1)

DOI: 10.1155/humu/9607360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, online erschienen am 19.08.2026. Verfasst von Deyi Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China, zju.edu.cn. Hauptthemen laut MEDLINE: Stomach Neoplasms, Cisplatin, Mutation, Cancer-Associated Fibroblasts. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin response in gastric cancer is shaped by malignant cell programs, stromal states, and mutation‐immune crosstalk, but the CAF subtypes linked to platinum tolerance and their epithelial effectors remain incompletely defined. We integrated single‐cell RNA sequencing, epithelial CNV‐like inference, fibroblast reclustering, CellChat analysis, signature scoring, hdWGCNA, CAF‐epithelial coupling, exploratory GSE14209 evaluation, TCGA‐STAD mutation/copy‐number contextualization, and DepMap CRISPR virtual knockout analysis, followed by experimental validation in AGS and HGC‐27 cells. IGF1+ CXCL12+ CAFs showed resistance‐supportive stromal features, and CAF‐epithelial coupling prioritized ARPC1A as a tumor epithelial candidate associated with this stromal program. In TCGA‐STAD, ARPC1A mutations were rare and consisted of three missense and two frameshift variants without a recurrent hotspot; the mutant tumors were confined to the MSI subtype and showed an immune‐activated, high TMB/MSI context, indicating mutation‐immune crosstalk rather than a clear mutation‐specific CAF, EMT, drug resistance, or cisplatin response phenotype. By contrast, ARPC1A copy‐number gain/amplification was more frequent and tracked with ARPC1A expression, CIN enrichment, aneuploidy, and fraction of genome altered. DepMap CRISPR data indicated mostly weak‐to‐mild baseline ARPC1A dependency in upper GI and gastric/GEJ models. Experimentally, ARPC1A knockdown increased cisplatin sensitivity, promoted cisplatin‐induced apoptosis, and suppressed migration and invasion. These findings identify a CAF‐associated ARPC1A epithelial program linked to cisplatin response and support a mutation‐immune/copy‐number framework in which ARPC1A is interpreted mainly through immune‐contextual mutation patterns and expression dosage rather than recurrent gain‐of‐function mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsCisplatinMutationCancer-Associated FibroblastsHumansDrug Resistance, NeoplasmCell Line, TumorGene Expression Regulation, NeoplasticAntineoplastic AgentsTumor MicroenvironmentDNA Copy Number Variations

Stichwörter der Autor:innen

ARPC1ADepMap CRISPR screeningcancer-associated fibroblastscisplatin resistancecopy-number alterationgastric cancersingle-cell RNA sequencingtumor microenvironment

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China, zju.edu.cn.
  • Department of Pathology, Nanjing Drum Tower Hospital Group Suqian Hospital, Suqian, Jiangsu, China.
  • Department of Clinical Laboratory, Zhejiang Jinhua Guangfu Cancer Hospital, Jinhua, Zhejiang, China.
  • Department of Clinical Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China, zju.edu.cn.
  • Department of Hepatobiliary and Pancreatic Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China, zju.edu.cn.
  • Department of Hepatology, Huai'an Fourth People's Hospital, Huai'an, China.

ORCID-Profile: Jiahao Ge, Qing Zhang, Qi Min

Zitieren

APA

Lu, D., Meng, F., Zhou, W., Hu, Y., Li, G., Ge, J., Zhang, Q., & Min, Q. (2026). Mutation‐Immune Crosstalk Contextualizes CAF‐Associated ARPC1A Programs and Cisplatin Response in Gastric Cancer. Human Mutation, 2026(1). https://doi.org/10.1155/humu/9607360

Vancouver

Lu D, Meng F, Zhou W, Hu Y, Li G, Ge J, et al. Mutation‐Immune Crosstalk Contextualizes CAF‐Associated ARPC1A Programs and Cisplatin Response in Gastric Cancer. Human Mutation. 2026;2026(1). doi:10.1155/humu/9607360

BibTeX
@article{Lu2026,
  author = {Lu, Deyi and Meng, Fanlai and Zhou, Weiying and Hu, Yifei and Li, Gaosha and Ge, Jiahao and Zhang, Qing and Min, Qi},
  title = {Mutation‐Immune Crosstalk Contextualizes CAF‐Associated ARPC1A Programs and Cisplatin Response in Gastric Cancer},
  journal = {Human Mutation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/humu/9607360}
}
Kostenlos starten →